Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

CD30 Expression in Malignant Vascular Tumors and Its Diagnostic and Clinical Implications A Study of 146 Cases

CD30 Expression in Malignant Vascular Tumors and Its Diagnostic and Clinical Implications A... RESEARCH ARTICLE CD30 Expression in Malignant Vascular Tumors and Its Diagnostic and Clinical Implications: A Study of 146 Cases Meghna Alimchandani, MD, Zeng-Feng Wang, PhD, and Markku Miettinen, MD ngiosarcoma (AS) is a rare, usually high-grade ma- Abstract: Angiosarcoma (AS) is a rare malignant vascular tumor, Alignant vascular endothelial tumor comprising <1% whereas epithelioid hemangioendothelioma (EHE) is a vascular of all sarcomas. It most commonly involves skin and less tumor of low-grade malignancy. CD30 is a member of the tumor commonly deep soft tissue, breast parenchyma, liver, spleen, necrosis factor receptor superfamily, member 8 (TNFRSF8). Al- 1–3 and bone. Histologically ASs vary from spindled to epi- though the expression of CD30 is most commonly associated with thelioid morphology. Poorly differentiated AS with limited lymphoid malignancies or germ cell tumors, occasional ASs have vasoformation and solid growth patterns may simulate been reported as CD30 positive. However, there are limited data to other malignancies, such as carcinoma, melanoma, and even evaluate its role definitively in malignant vascular tumors. In this lymphoma, thus prompting a wide differential diagnosis. study, we evaluated 91 ASs, 30 EHEs from various sites, and 25 Epithelioid hemangioendothelioma (EHE) is a low-grade Kaposi sarcomas. Overall, CD30 was expressed http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

CD30 Expression in Malignant Vascular Tumors and Its Diagnostic and Clinical Implications A Study of 146 Cases

Loading next page...
 
/lp/wolters-kluwer-health/cd30-expression-in-malignant-vascular-tumors-and-its-diagnostic-and-yE0lfjmcPi
Copyright
Copyright © 2014 by Lippincott Williams & Wilkins
ISSN
1541-2016
DOI
10.1097/PAI.0000000000000048
pmid
24805132
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE CD30 Expression in Malignant Vascular Tumors and Its Diagnostic and Clinical Implications: A Study of 146 Cases Meghna Alimchandani, MD, Zeng-Feng Wang, PhD, and Markku Miettinen, MD ngiosarcoma (AS) is a rare, usually high-grade ma- Abstract: Angiosarcoma (AS) is a rare malignant vascular tumor, Alignant vascular endothelial tumor comprising <1% whereas epithelioid hemangioendothelioma (EHE) is a vascular of all sarcomas. It most commonly involves skin and less tumor of low-grade malignancy. CD30 is a member of the tumor commonly deep soft tissue, breast parenchyma, liver, spleen, necrosis factor receptor superfamily, member 8 (TNFRSF8). Al- 1–3 and bone. Histologically ASs vary from spindled to epi- though the expression of CD30 is most commonly associated with thelioid morphology. Poorly differentiated AS with limited lymphoid malignancies or germ cell tumors, occasional ASs have vasoformation and solid growth patterns may simulate been reported as CD30 positive. However, there are limited data to other malignancies, such as carcinoma, melanoma, and even evaluate its role definitively in malignant vascular tumors. In this lymphoma, thus prompting a wide differential diagnosis. study, we evaluated 91 ASs, 30 EHEs from various sites, and 25 Epithelioid hemangioendothelioma (EHE) is a low-grade Kaposi sarcomas. Overall, CD30 was expressed

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: May 1, 2014

There are no references for this article.